Discontinuation of secondary prophylaxis for Pneumocystis pneumonia in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy

Pediatric Infectious Disease Journal

Volumn 24, Issue 12, 2005, Pages 1117-1120

  Esposito, Susanna ^a   Bojanin, Jelena ^a   Porta, Alessandro ^a   Cesati, Laura ^a   Gualtieri, Laura ^a   Principi, Nicola ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Highly active antiretroviral therapy; Human immunodeficiency virus infection; Opportunistic infections; Pneumocystis pneumonia; Prophylaxis

Indexed keywords

CD4 ANTIGEN; COTRIMOXAZOLE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; PENTAMIDINE; RITONAVIR; STAVUDINE;

ARTICLE; CELL COUNT; CLINICAL ARTICLE; CONVALESCENCE; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION PREVENTION; MALE; PATIENT SAFETY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 29444458876     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000190038.53813.d2     Document Type: Article

References (12)

1. Lopez Bernaldo deq Uiros JC, Miró JM, Pena JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. N Engl J Med. 2001;344:159-167.
2. Mussini C, Pezzotti P, Antinori A, et al. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP study group. Clin Infect Dis. 2003;36:645-651.
3. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons: 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep. 2002;51:1-52.
4. Atzori C, Clerici M, Trabattoni D, et al. Assessment of immune reconstitution to Pneumocystis carinii in HIV-1 patients under different highly active antiretroviral therapy regimens. J Antimicrob Chemiother. 2003;52:276-281.
5. Hirsch HH, Kaufmann G, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis. 2004;38:1159-1166.
6. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Available at: http//www.aidsinfo. nih.gov. Accessed June 29, 2005.
7. Ruffini DD, Madhi SA. The high burden of Pneumocystis carinii pneumonia in African HIV-1-infected children hospitalized for severe pneumonia. AIDS. 2002;16:105-112.
8. Chintu C, Bhat GJ, Walker AS, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet. 2004;364:1865-1871.
9. Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis. 2004;10:10:1713-1720.
10. Mofenson LM, Oleske J, Serchuck L, et al. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep. 2004;53(RR-14):1-92.
11. Grimwade K, Swingler G. Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection. Cochrane Database Syst Rev. 2003;2:CD003508.
12. Nachman S, Gona P, Dankner W, et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics. 2005;115:e488-e494.